Press Releases

Press Releases
Date Title and Summary View
Dec 6, 2016 Interim study findings further support safety, efficacy and tolerability in squamous and elderly patients with advanced NSCLC, consistent with results previously seen in the pivotal Phase III trial BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced inter...
Dec 5, 2016 Patients with MDS, CMML or AML who were relapsed or refractory to prior HMA therapies and who received CC-486 had a 38% overall response rate SUMMIT, N.J.--(BUSINESS WIRE)-- Abstract #905 -- Celgene Corporation (NASDAQ:CELG), today announced results from an analysis of three phase I...
Dec 3, 2016 Project will create the largest dataset of molecular profiling for patients with multiple myeloma leading to tests that could improve diagnosis, prognosis and new treatments SAN DIEGO--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG), Dana-Farber Cancer Institute and the Universi...
Nov 22, 2016 Presentations will focus on a wide range of disease areas including multiple myeloma, lymphoma, leukemia, myelodysplastic syndromes and beta-thalassemia SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that data from nearly 350 abstracts, including m...
Nov 21, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to webcast an analyst and investor event being held at the American Society of Hematology (ASH) meeting in San Diego on December 4. The webcast will begin at 11pm ET and will be available in the Investor Relations section of the Company's ...
Nov 14, 2016 ACTIVE trial in biologic-naïve patients met its primary endpoint, demonstrating significant improvement in ACR20 response rate at week 16 with OTEZLA versus placebo Improvements in ACR20 and other measures of disease seen as early as week 2 ACR20 response rate increas...
Oct 27, 2016 - Net Product Sales $2.97B in Q3:16; Increased 28% Y/Y - 2016 Guidance and 2017 Targets Updated - Over 150 Abstracts Expected at Medical Congresses in Q4 - FDA Grants Priority Review for REVLIMID® as Maintenance Treatment Post-Autologous Stem-Cell Transplant in...
Oct 24, 2016 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences in November where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the ...
Oct 18, 2016 Observational study to examine the burden of chronic anemia in myelodysplastic syndromes and beta-thalassemia SUMMIT, N.J. & SEATTLE--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Sage Bionetworks today announced a collaboration to develop an iPhone application utilizing the Apple...
Oct 17, 2016 Open-label extension of TOUCHSTONE study of ozanimod showed continued symptom improvement through week 44 of the extension Safety and tolerability were consistent with previous studies of ozanimod VIENNA--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly ow...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase